Illumina's Q4 Revenues Rise 24 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Monday that its fourth-quarter revenues climbed 24 percent, topping analysts' consensus estimate.

The San Diego-based genetic analysis products firm brought in total revenues of $309.3 million for the three months ended Dec. 30, 2012, in line with its pre-announcement and up from $250.1 million for the fourth quarter of 2011. It beat the consensus Wall Street estimate of $305.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.